Ery Olivianto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ery Olivianto has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Agustin Iskandar
Biomedical Central Laboratory, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
4 shared publications - Betty Weri Yolanda Nababan
Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta 55281, Indonesia
2 shared publications - Diah Asri Wulandari
Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia
2 shared publications - Finny Fitry Yani
Department of Child Health Faculty of Medicine Andalas University Padang Indonesia
2 shared publications - Fransiska Meyanti
CV Data Narya Amerta Semesta, Jakarta 13330, Indonesia
2 shared publications - Muhammad Buston Ardiyamustaqim
Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta 55281, Indonesia
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- Vol. 10 (3) , 122-132
Pilot Randomized Trial of Vitamin D and Zinc Supplementation on Total Adenosine Deaminase in Pediatric Tuberculosis
Pediatric tuberculosis remains difficult to monitor using objective biomarkers. Total serum adenosine deaminase (ADA) reflects cellular immune activation, whereas vitamin D and zinc may modify antimycobacterial immunity. This pilot randomized trial evaluated whether adjunctive vitamin D or zinc altered serum ADA during the intensive phase of pediatric tuberculosis treatment. Thirty-three treatment-naive children with tuberculosis were randomized equally to standard anti-tuberculosis treatment (ATT) alone, ATT plus zinc, or ATT plus vitamin D. Total serum ADA was measured at baseline and after two months. The prespecified completer analysis compared change scores, while the primary adjusted analysis used analysis of covariance (ANCOVA) with post-treatment ADA as the outcome and baseline ADA as a covariate. A multiple-imputation intention-to-treat sensitivity analysis included all randomized participants. Twenty-two participants completed follow-up (ATT, n = 8; zinc, n = 8; vitamin D, n = 6). Unadjusted ADA decreased in all groups and most markedly in the vitamin D arm, but the between-group difference in change was not significant (p = 0.364). Baseline-adjusted ANCOVA also showed no treatment-group difference (F2,18 = 0.79; p = 0.470). Compared with ATT alone, the adjusted effects were −4.35 U/L for vitamin D (95% CI −15.70 to 7.00) and +2.26 U/L for zinc (95% CI −8.07 to 12.59). The intention-to-treat sensitivity analysis produced the same overall interpretation. In this underpowered pilot trial, adjunctive vitamin D or zinc did not significantly reduce total serum ADA beyond standard therapy. The large crude decline in the vitamin D arm was attenuated after adjustment for baseline imbalance and regression to the mean. Larger multicentre trials should confirm micronutrient repletion, measure ADA2, and prespecify methods for missing data.
- 1 September 2026
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- Vol. 10 (3) , 122-132
Open AccessPilot Randomized Trial of Vitamin D and Zinc Supplementation on Total Adenosine Deaminase in Pediatric Tuberculosis
Pediatric tuberculosis remains difficult to monitor using objective biomarkers. Total serum adenosine deaminase (ADA) reflects cellular immune activation, whereas vitamin D and zinc may modify antimycobacterial immunity. This pilot randomized trial evaluated whether adjunctive vitamin D or zinc altered serum ADA during the intensive phase of pediatric tuberculosis treatment. Thirty-three treatment-naive children with tuberculosis were randomized equally to standard anti-tuberculosis treatment (ATT) alone, ATT plus zinc, or ATT plus vitamin D. Total serum ADA was measured at baseline and after two months. The prespecified completer analysis compared change scores, while the primary adjusted analysis used analysis of covariance (ANCOVA) with post-treatment ADA as the outcome and baseline ADA as a covariate. A multiple-imputation intention-to-treat sensitivity analysis included all randomized participants. Twenty-two participants completed follow-up (ATT, n = 8; zinc, n = 8; vitamin D, n = 6). Unadjusted ADA decreased in all groups and most markedly in the vitamin D arm, but the between-group difference in change was not significant (p = 0.364). Baseline-adjusted ANCOVA also showed no treatment-group difference (F2,18 = 0.79; p = 0.470). Compared with ATT alone, the adjusted effects were −4.35 U/L for vitamin D (95% CI −15.70 to 7.00) and +2.26 U/L for zinc (95% CI −8.07 to 12.59). The intention-to-treat sensitivity analysis produced the same overall interpretation. In this underpowered pilot trial, adjunctive vitamin D or zinc did not significantly reduce total serum ADA beyond standard therapy. The large crude decline in the vitamin D arm was attenuated after adjustment for baseline imbalance and regression to the mean. Larger multicentre trials should confirm micronutrient repletion, measure ADA2, and prespecify methods for missing data.
- Open Access
- 14 April 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (4) , 106
Treatment-Decision Algorithm of Child TB: Evaluation of WHO Algorithm and Development of Indonesia Algorithm
Clinical algorithms for child tuberculosis (TB) are a valuable guide for healthcare workers to initiate treatment. We evaluated the agreement of pediatric TB diagnosis using the current Indonesia diagnostic algorithms with the 2022 WHO treatment decision algorithm and developed a new Indonesia algorithm for child TB based upon our findings and expert opinion. We conducted a retrospective study at 10 hospitals in Indonesia, involving children (0–10 years), who were evaluated for TB diagnosis in 2022. A panel of child TB experts used participants’ records to make a diagnosis using the 2022 WHO algorithm and the 2016 Indonesian algorithm. We assessed agreement between the diagnosis made by the attending doctor and those determined by the expert panel. A new Indonesia guideline was developed based on the findings and consensus of various stakeholders. Of 523 eligible children, 371 (70.9%) were diagnosed with TB by the attending doctors, 295 (56.4%) by the WHO algorithm, and 246 (47%) by the Indonesia algorithm. The Cohen’s Kappa of TB diagnosis was: attending doctor vs. WHO algorithm (0.27), attending doctor vs. Indonesia algorithm (0.45), and WHO algorithm vs. Indonesia algorithm (0.42). A review of both algorithms revealed challenges for implementation. An algorithmic approach for child TB diagnosis may not be universally applicable or implementable due to variable access to diagnostic tests and the wide variety of clinical presentations.
- 14 April 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (4) , 106
Open AccessTreatment-Decision Algorithm of Child TB: Evaluation of WHO Algorithm and Development of Indonesia Algorithm
Clinical algorithms for child tuberculosis (TB) are a valuable guide for healthcare workers to initiate treatment. We evaluated the agreement of pediatric TB diagnosis using the current Indonesia diagnostic algorithms with the 2022 WHO treatment decision algorithm and developed a new Indonesia algorithm for child TB based upon our findings and expert opinion. We conducted a retrospective study at 10 hospitals in Indonesia, involving children (0–10 years), who were evaluated for TB diagnosis in 2022. A panel of child TB experts used participants’ records to make a diagnosis using the 2022 WHO algorithm and the 2016 Indonesian algorithm. We assessed agreement between the diagnosis made by the attending doctor and those determined by the expert panel. A new Indonesia guideline was developed based on the findings and consensus of various stakeholders. Of 523 eligible children, 371 (70.9%) were diagnosed with TB by the attending doctors, 295 (56.4%) by the WHO algorithm, and 246 (47%) by the Indonesia algorithm. The Cohen’s Kappa of TB diagnosis was: attending doctor vs. WHO algorithm (0.27), attending doctor vs. Indonesia algorithm (0.45), and WHO algorithm vs. Indonesia algorithm (0.42). A review of both algorithms revealed challenges for implementation. An algorithmic approach for child TB diagnosis may not be universally applicable or implementable due to variable access to diagnostic tests and the wide variety of clinical presentations.
- Open Access
- 28 March 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- Vol. 9 (2) , 60-72
The Relationship of Vitamin D and IL-17 Levels with Disease Severity in Pediatric Tuberculosis Patients
Tuberculosis (TB) remains a significant global health burden, particularly in children, where immune responses play a crucial role in disease progression. The objective of this research was to analyze the relationship of vitamin D and IL-17 levels with the severity of pediatric TB. This observational analytic study was conducted at Dr. Saiful Anwar Hospital, Malang, involving 33 pediatric patients diagnosed with TB, divided into mild (n = 8), moderate (n = 18) and severe (n = 7) groups. Severity was determined using the score developed in this study. Vitamin D levels were measured using the Cobas c501 analyzer, and IL-17 levels were measured using the Human IL-17 ELISA Kit. While Vitamin D level was significantly lower in microbiologically confirmed patients (p = 0.038), it was not significantly different among severity groups (p = 0.799). Meanwhile, IL-17 levels were significantly higher in patients with more severe respiratory distress (p = 0.01), although the difference between severity groups was not statistically significant (p = 0.966). Furthermore, there was no correlation between vitamin D levels and IL-17 levels (r = 0.178, p = 0.322). These findings indicate the need for further research to explore vitamin D supplementation as an adjunctive therapy and to evaluate IL-17 as a biomarker for disease activity.
- 28 March 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- Vol. 9 (2) , 60-72
Open AccessThe Relationship of Vitamin D and IL-17 Levels with Disease Severity in Pediatric Tuberculosis Patients
Tuberculosis (TB) remains a significant global health burden, particularly in children, where immune responses play a crucial role in disease progression. The objective of this research was to analyze the relationship of vitamin D and IL-17 levels with the severity of pediatric TB. This observational analytic study was conducted at Dr. Saiful Anwar Hospital, Malang, involving 33 pediatric patients diagnosed with TB, divided into mild (n = 8), moderate (n = 18) and severe (n = 7) groups. Severity was determined using the score developed in this study. Vitamin D levels were measured using the Cobas c501 analyzer, and IL-17 levels were measured using the Human IL-17 ELISA Kit. While Vitamin D level was significantly lower in microbiologically confirmed patients (p = 0.038), it was not significantly different among severity groups (p = 0.799). Meanwhile, IL-17 levels were significantly higher in patients with more severe respiratory distress (p = 0.01), although the difference between severity groups was not statistically significant (p = 0.966). Furthermore, there was no correlation between vitamin D levels and IL-17 levels (r = 0.178, p = 0.322). These findings indicate the need for further research to explore vitamin D supplementation as an adjunctive therapy and to evaluate IL-17 as a biomarker for disease activity.
- Open Access
- 4 March 2025
- Published by Sanglah Hospital - Udayana University in Pediatric Sciences Journal
- Vol. 6 (1) , 13-17
A comparison of test duration for the clinical diagnosis of pediatric tuberculosis using Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRA)
Background: Tuberculosis (TB) remains a major global health challenge, particularly among children. Diagnosing pediatric TB is complicated due to nonspecific symptoms and the difficulty of obtaining sputum samples for microbiological confirmation. Immunological tests, such as the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), are commonly used to support diagnosis. However, TST has several limitations, including the need for multiple patient visits and potential cross-reactivity with Bacillus Calmette-Guérin (BCG) vaccination. This study aimed to compare the efficiency of IGRA and TST in terms of turnaround time and patient compliance. Methods: A diagnostic time comparison study was conducted in pediatric patients with suspected pulmonary or extrapulmonary TB at Saiful Anwar Hospital, Malang. Patients underwent both TST and IGRA testing. The time required to obtain results and patient compliance was recorded and analyzed. o Results: A total of 94 pediatric patients were included, with 17 diagnosed with extrapulmonary TB and 77 with pulmonary TB. IGRA demonstrated a significantly shorter turnaround time (25.43 ± 6.31 hours for pulmonary TB, and 25.58 ± 6.37 hours for extrapulmonary TB) compared to TST (50.16 ± 6,93 hours for extrapulmonary TB and 50.34 ± 7.16 hours for pulmonary TB). Additionally, IGRA provided higher positivity rates in both pulmonary and extrapulmonary TB cases. Conclusion: IGRA offers a faster and more convenient alternative to TST for diagnosing pediatric TB. Despite its higher cost, the efficiency and single-visit requirement of IGRA makes it a preferable diagnostic tool in clinical settings, especially for children suspected of having TB.
- 4 March 2025
- Published by Sanglah Hospital - Udayana University in Pediatric Sciences Journal
- Vol. 6 (1) , 13-17
Open AccessA comparison of test duration for the clinical diagnosis of pediatric tuberculosis using Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRA)
Background: Tuberculosis (TB) remains a major global health challenge, particularly among children. Diagnosing pediatric TB is complicated due to nonspecific symptoms and the difficulty of obtaining sputum samples for microbiological confirmation. Immunological tests, such as the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), are commonly used to support diagnosis. However, TST has several limitations, including the need for multiple patient visits and potential cross-reactivity with Bacillus Calmette-Guérin (BCG) vaccination. This study aimed to compare the efficiency of IGRA and TST in terms of turnaround time and patient compliance. Methods: A diagnostic time comparison study was conducted in pediatric patients with suspected pulmonary or extrapulmonary TB at Saiful Anwar Hospital, Malang. Patients underwent both TST and IGRA testing. The time required to obtain results and patient compliance was recorded and analyzed. o Results: A total of 94 pediatric patients were included, with 17 diagnosed with extrapulmonary TB and 77 with pulmonary TB. IGRA demonstrated a significantly shorter turnaround time (25.43 ± 6.31 hours for pulmonary TB, and 25.58 ± 6.37 hours for extrapulmonary TB) compared to TST (50.16 ± 6,93 hours for extrapulmonary TB and 50.34 ± 7.16 hours for pulmonary TB). Additionally, IGRA provided higher positivity rates in both pulmonary and extrapulmonary TB cases. Conclusion: IGRA offers a faster and more convenient alternative to TST for diagnosing pediatric TB. Despite its higher cost, the efficiency and single-visit requirement of IGRA makes it a preferable diagnostic tool in clinical settings, especially for children suspected of having TB.
- Open Access
- 1 February 2025
- Published by SAGE Publications in Sage Open Pediatrics
- Vol. 12
Policy-Practice Gaps in the Management of Asthma in Children in a Developing Country: Indonesia Experience
Objective . Sub-optimal management of childhood asthma in developing countries has been a recognized issue for decades. Our study aimed to evaluate actual practice in the management of asthma among pediatricians in Indonesia and identify gaps to the national guideline. Methods. We conducted an online survey involving 1386 pediatricians from 37 of 38 provinces in Indonesia, representing 28.8% of the pediatricians registered in the Indonesian Pediatric Society. Results. While nebulizers and inhaled reliever medications were widely available, inhaled corticosteroids medications and spirometer were scarce. Only 16.2% of pediatricians used spirometer to support the diagnosis. Meanwhile, routine blood counts and chest X-ray were commonly performed, and nearly 90% of pediatricians reported prescribing oral short acting β2-agonist as relievers, which is inconsistent with guidelines. Conclusion . There are significant gaps between national guidelines and actual practices in childhood asthma management in Indonesia, which may be due to disparities and barriers to medication access.
- 1 February 2025
- Published by SAGE Publications in Sage Open Pediatrics
- Vol. 12
Open AccessPolicy-Practice Gaps in the Management of Asthma in Children in a Developing Country: Indonesia Experience
Objective . Sub-optimal management of childhood asthma in developing countries has been a recognized issue for decades. Our study aimed to evaluate actual practice in the management of asthma among pediatricians in Indonesia and identify gaps to the national guideline. Methods. We conducted an online survey involving 1386 pediatricians from 37 of 38 provinces in Indonesia, representing 28.8% of the pediatricians registered in the Indonesian Pediatric Society. Results. While nebulizers and inhaled reliever medications were widely available, inhaled corticosteroids medications and spirometer were scarce. Only 16.2% of pediatricians used spirometer to support the diagnosis. Meanwhile, routine blood counts and chest X-ray were commonly performed, and nearly 90% of pediatricians reported prescribing oral short acting β2-agonist as relievers, which is inconsistent with guidelines. Conclusion . There are significant gaps between national guidelines and actual practices in childhood asthma management in Indonesia, which may be due to disparities and barriers to medication access.
- Open Access
- 6 January 2025
- Published by MDPI AG in Preprints.org
Treatment-Decision Algorithm of Child TB: Evaluation of Who Algorithm and Development of Indonesia Algorithm
Clinical algorithms for child tuberculosis (TB) are a valuable guide for healthcare-workers to initiate treatment. We evaluated the 2022 WHO treatment decision algorithm and developed a new Indonesia algorithm for child TB. We conducted a retrospective study at 10 hospitals in Indonesia, involving children (0-10 years), who were evaluated for TB diagnosis in 2022. A panel of child TB experts used participant’s records to make a diagnosis using the 2022 WHO algorithm and the 2016 Indonesian algorithm. We assessed agreement between the diagnosis made by the attending doctor and those determined by the expert panel. A new Indonesia guideline was developed based on the findings and consensus of various stakeholders. Of 523 eligible children, 371 (70.9%) were diagnosed with TB by the attending doctors, 295 (56.4%) by WHO algorithm, and 246 (47%) by Indonesia algorithm. The Cohen’s Kappa of TB diagnosis was: attending doctor vs WHO algorithm (0.27), attending doctor vs Indonesia algorithm (0.45), and WHO algorithm vs Indonesia algorithm (0.42). A detailed review of both algorithms revealed limitations for implementation. An algorithmic approach for child TB diagnosis may not be universally applicable or implementable due to variable access to diagnostic tests and wide variety of clinical presentations.
- 6 January 2025
- Published by MDPI AG in Preprints.org
Open AccessTreatment-Decision Algorithm of Child TB: Evaluation of Who Algorithm and Development of Indonesia Algorithm
Clinical algorithms for child tuberculosis (TB) are a valuable guide for healthcare-workers to initiate treatment. We evaluated the 2022 WHO treatment decision algorithm and developed a new Indonesia algorithm for child TB. We conducted a retrospective study at 10 hospitals in Indonesia, involving children (0-10 years), who were evaluated for TB diagnosis in 2022. A panel of child TB experts used participant’s records to make a diagnosis using the 2022 WHO algorithm and the 2016 Indonesian algorithm. We assessed agreement between the diagnosis made by the attending doctor and those determined by the expert panel. A new Indonesia guideline was developed based on the findings and consensus of various stakeholders. Of 523 eligible children, 371 (70.9%) were diagnosed with TB by the attending doctors, 295 (56.4%) by WHO algorithm, and 246 (47%) by Indonesia algorithm. The Cohen’s Kappa of TB diagnosis was: attending doctor vs WHO algorithm (0.27), attending doctor vs Indonesia algorithm (0.45), and WHO algorithm vs Indonesia algorithm (0.42). A detailed review of both algorithms revealed limitations for implementation. An algorithmic approach for child TB diagnosis may not be universally applicable or implementable due to variable access to diagnostic tests and wide variety of clinical presentations.
- Open Access
- 1 September 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (9) , 1183-1192
Diagnostic Performance of IL-1β and C-Reactive Protein in Childhood Tuberculosis
Interleukin (IL)-1β, a proinflammatory cytokine produced by phagocytes infected with Mycobacterium tuberculosis, is known for its stability in storage, which ensures consistent measurement in clinical settings. This stability, along with its unaffected levels by age, sex, or lung disease severity, makes IL-1β a promising biomarker in tuberculosis (TB). This study aims to evaluate the diagnostic performance of IL-1β and C-reactive protein (CRP) in childhood TB. cross-sectional study was conducted on 77 children with suspected TB at Saiful Anwar Hospital. The inclusion criteria were based on the 2016 technical guidelines for TB. IL-1β levels were measured using Elisa, while CRP was assessed via immunoturbidimetry. A significant difference in mean IL-1β levels was observed between the TB and non-TB groups (p = 0.028). However, IL-1β showed a weak correlation with the TB group (r = 0.251, p = 0.027). The area under the curve (AUC) for IL-1β was 0.671 (p = 0.028) with 52.5% sensitivity, 83.3% specificity, 91.1% positive predictive value (PPV), 34.8% negative predictive value (NPV), and 59.7% accuracy at a cut-off of 6.1 pg/mL. CRP levels showed no significant correlation or difference between the groups. The combination of IL-1β and CRP yielded an AUC of 0.669 (p = 0.031), with 41.5% sensitivity, 75% specificity, 84.4% PPV, 28.1% NPV, and 49.3% accuracy. Although IL-1β shows moderate diagnostic performance and CRP alone or combined with IL-1β has limited utility in diagnosing childhood TB, IL-1β still holds potential as a biomarker. Its high positive predictive value (PPV) indicates strong reliability in confirming TB, making it a valuable tool in a broader diagnostic or monitoring of childhood TB.
- 1 September 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (9) , 1183-1192
Open AccessDiagnostic Performance of IL-1β and C-Reactive Protein in Childhood Tuberculosis
Interleukin (IL)-1β, a proinflammatory cytokine produced by phagocytes infected with Mycobacterium tuberculosis, is known for its stability in storage, which ensures consistent measurement in clinical settings. This stability, along with its unaffected levels by age, sex, or lung disease severity, makes IL-1β a promising biomarker in tuberculosis (TB). This study aims to evaluate the diagnostic performance of IL-1β and C-reactive protein (CRP) in childhood TB. cross-sectional study was conducted on 77 children with suspected TB at Saiful Anwar Hospital. The inclusion criteria were based on the 2016 technical guidelines for TB. IL-1β levels were measured using Elisa, while CRP was assessed via immunoturbidimetry. A significant difference in mean IL-1β levels was observed between the TB and non-TB groups (p = 0.028). However, IL-1β showed a weak correlation with the TB group (r = 0.251, p = 0.027). The area under the curve (AUC) for IL-1β was 0.671 (p = 0.028) with 52.5% sensitivity, 83.3% specificity, 91.1% positive predictive value (PPV), 34.8% negative predictive value (NPV), and 59.7% accuracy at a cut-off of 6.1 pg/mL. CRP levels showed no significant correlation or difference between the groups. The combination of IL-1β and CRP yielded an AUC of 0.669 (p = 0.031), with 41.5% sensitivity, 75% specificity, 84.4% PPV, 28.1% NPV, and 49.3% accuracy. Although IL-1β shows moderate diagnostic performance and CRP alone or combined with IL-1β has limited utility in diagnosing childhood TB, IL-1β still holds potential as a biomarker. Its high positive predictive value (PPV) indicates strong reliability in confirming TB, making it a valuable tool in a broader diagnostic or monitoring of childhood TB.